Clinical trials: Malignant Breast Neoplasm
Gastric Cancer, Colon Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer
- Trial name
- NCT06010862
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Breast Neoplasm
A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)
Women with metastatic breast cancer are usually treated with anthracyclines (ie, doxorubicin or epirubicin) but cardiac toxicity limits their use.
- Trial name
- NCT00779129
- Testing
- Pegylated Lyposomal Doxorubicin, Cyclophosphamide
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer Detection, Breast Neoplasm
Molecular Breast Imaging (MBI)-Guided Biopsy
The goal of this pilot clinical trial is to demonstrate supplemental screening MBI (molecular breast imaging) in women with dense breasts.
- Conditions
- Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy
- Trial name
- MBI-GB-Pilot (NCT07114679)
- Testing
- Molecular Breast Imaging, MBI-guided biopsy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Smart Breast Corp.
Breast Cancer Female, Breast Neoplasm Female
An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)
The purpose of this observational study is to evaluate real-world safety and efficacy of pegfilgrastim (Neulasta) administered as secondary prophylaxis in Korean female patients with breast cancer receiving chemotherapy regimens…
- Trial name
- NCT03433560
- Where
- 3 sites in South Korea
- Volunteers
- 1,300 people
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Breast Cancer
Collection of FUJIFILM's 3Dimensional Mammograms
This image-acquisition study is designed to acquire the study image data and establish and document the clinical findings for each subject.
- Trial name
- 3DM (NCT01542814)
- Testing
- 3Dimensional Mammography, 2D FFDM
- Where
- 3 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Fujifilm Medical Systems USA, Inc.
Breast Neoplasm
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
In this study the investigators assess the impact of the eHealth-supported therapy management system CANKADO on Quality of Life in patients with HR+, HER2-locally advanced or metastatic breast cancer treated with the cyclin…
- Trial name
- PRECYCLE (NCT03220178)
- Testing
- Palbociclib, Fulvestrant, Anastrozole
- Where
- Germany
- Volunteers
- 532 people
- Sponsor
- Palleos Healthcare GmbH
Breast Cancer, Breast Neoplasm
Combination Study of SV-BR-1-GM With Retifanlimab
This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy.
- Conditions
- Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
- Trial name
- NCT03328026
- Testing
- SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation
- Where
- 14 sites in United States
- Volunteers
- 36 people
- Sponsor
- BriaCell Therapeutics Corporation
Endometrial Cancer, Cervical Cancer
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Conditions
- Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
- Trial name
- NCT06293898
- Testing
- BL-M07D1
- Where
- 26 sites in United States
- Volunteers
- 280 people
- Sponsor
- SystImmune Inc.
Breast Neoplasm
Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®
This non-interventional study is designated as a Post Marketing Surveillance Study and is a commitment to Ministry of Food and Drug Safety (MFDS).
- Trial name
- NCT03445637
- Where
- South Korea
- Volunteers
- 552 people
- Sponsor
- Pfizer
Breast Neoplasm
SAVI SCOUT Clinical Evaluation Study
The purpose of this study is to evaluate the performance of the SAVI SCOUT® Surgical Guidance System (SAVI SCOUT). The SAVI SCOUT is a medical device, used to provide real-time guidance during localized excisional biopsy or…
- Trial name
- NCT02370082
- Testing
- Localization of breast lesion
- Volunteers
- 150 people
- Sponsor
- Cianna Medical, Inc.
TNBC - Triple-Negative Breast Cancer, HR+ Breast Cancer
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.
- Trial name
- NCT07080619
- Testing
- SC-101
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
To determine how long Gemcitabine and Bevacizumab will stop the cancer from growing in patients with advanced breast cancer.
- Trial name
- NCT00623233
- Testing
- Gemcitabine, Bevacizumab
- Where
- 16 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Exploratory Study Comparing ClearSight System 2D Map to Post Surgery Histopathological Analysis in Lumpectomy
Prospective, single-arm, multicenter, open label, non-randomized exploratory clinical study comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
- Trial name
- NCT02679378
- Testing
- ClearSight™ System
- Where
- 5 sites in United States, Israel
- Volunteers
- 220 people
- Sponsor
- Clear Cut Medical Ltd.
Breast Neoplasm
Real-life Pan-HER-blockade With Neratinib
So far, there is no data available on treatment of patients with early-stage hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer, who completed adjuvant…
- Trial name
- ELEANOR (NCT04388384)
- Testing
- Neratinib
- Where
- 97 sites in Austria, Germany and 1 more
- Volunteers
- 304 people
- Sponsor
- Pierre Fabre Pharma GmbH
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Breast Cancer, Advanced Malignant Solid Tumors
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information…
- Trial name
- NCT00706030
- Testing
- neratinib, vinorelbine
- Where
- 35 sites in United States, Belgium and 9 more
- Volunteers
- 92 people
- Sponsor
- Puma Biotechnology, Inc.
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic breast cancer undergoing surgery.
- Conditions
- Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast
- Trial name
- NCT03113825
- Testing
- Investigational Imaging device, AVB-620
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Avelas Biosciences, Inc.
Breast Neoplasm Malignant Female
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.
- Trial name
- NCT05134922
- Testing
- Gedatolisib
- Where
- 5 sites in United States
- Sponsor
- Celcuity Inc
Non-Small-Cell Lung Carcinoma, Malignant Melanoma
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may…
- Conditions
- Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
- Trial name
- PARADIGM (NCT05037825)
- Testing
- Checkpoint Inhibitor, Immune
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- VastBiome
Solid Tumors, Mycosis Fungoides
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.
- Conditions
- Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma
- Trial name
- NCT02890368
- Testing
- TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Pfizer